Sign inJoin waitlistJoin the waitlist

Partow Kebriaei

Associate Fellowship Director · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center Fellowship
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Chicago
2001–2002
Internal Medicine
1998–2001
University of Texas Southwestern Medical Center
1994–1998

Research

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Case report · Nature Reviews Clinical Oncology · 2018 · 1,951 citations
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
New England Journal of Medicine · 2020 · 1,804 citations
Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex
Proceedings of the National Academy of Sciences of the United States of America · 1995 · 637 citations

Richard Champlin
267 papers
Elizabeth Shpall
236 papers
Uday Popat
174 papers
Muzaffar Qazilbash
153 papers
Chitra Hosing
145 papers
Yago Nieto
125 papers
Amin Alousi
118 papers · 3 as a fellow
Qaiser Bashir
112 papers · 1 as a fellow
Betul Oran
101 papers · 2 as a resident
Issa Khouri
97 papers
Samer Srour
84 papers · 2 as a fellow
Marcos de Lima
79 papers

Clinical trials

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Principal investigator · Recruiting · Early phase 1
M.D. Anderson Cancer Center
2021–2032
CD19-Specific T Cells Post AlloSCT
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2020–2021
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2016–2022
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2015–2021